"Bempedoic Acid Shows Promise for LDL Lowering in High-risk Patients"
Treatment with bempedoic acid, an investigational oral, once-daily therapy that is designed to work in the liver to inhibit cholesterol biosynthesis, resulted in significant LDL reduction after 12 weeks compared with a placebo in patients at high risk for CV events who were receiving maximally tolerated statin and other lipid-lowering therapy enrolled in the CLEAR Wisdom trial. “The CLEAR Wisdom study evaluated the effects of bempedoic acid, an ATP-citrate lyase inhibitor, on LDL and CRP in a study of patients treated with moderate-to-high-intensity statins and a few people on low-intensity statins or no statins at all,” said Robert Rosenson, MD, professor of medicine, cardiology, and director of Cardiometabolic disorders at the Icahn School of Medicine at Mount Sinai. He added, “For early data, it was compelling, it was interesting and it seems directionally appropriate for that population intolerant to statins for muscle-related reasons.”
— Robert Rosenson, MD, Professor, Medicine, Cardiology, Director, Cardiometabolic Disorders, Icahn School of Medicine at Mount Sinai